ArticleBlood vessels, thrombosis & hemostasis2025
Low-molecular-weight heparin vs aspirin postpartum (LEAP): a single-center pilot randomized control trial.
Article in Blood vessels, thrombosis & hemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic role of low molecular weight heparin and fat-soluble vitamins in pregnancy-associated prethrombotic conditions.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low-molecular-weight heparin (LMWH) for 6 weeks postpartum for prophylaxis of venous thromboembolism (VTE) is suggested for patients with previous VTE or high-risk thrombophilia, yet evidence supporting this duration is limited. This study assesses the feasibility of a randomized controlled trial (RCT) comparing a shorter duration of LMWH postpartum. In a single-center pilot feasibility study, patients with previous VTE or high-risk thrombophilia were randomized to receive either 6 weeks of LMWH or a 3-week course of LMWH followed by 3 weeks of low-dose aspirin. We evaluated enrollment, adherence rates, and retention. Secondary outcomes included objectively confirmed VTE, bleeding events using the International Society on Thrombosis and Haemostasis criteria, and patient satisfaction via the Perception of Anti-Coagulant Treatment Questionnaire at 3 and 6 weeks postpartum. From October 2021 to July 2023, 67 individuals were screened, yielding a consent rate of 55%, with 30 participants enrolled. Fourteen patients were randomized to the LMWH group and 13 to the LMWH-aspirin group. Adherence was achieved in both groups (96.5% for LMWH, 93.9% for LMWH-aspirin,
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.